Cube Psytech Signs Exclusive Supply Agreement With Havn Life

July 8, 2021
News

Vancouver, BC – Cube Psytech Inc. (the “Company” or “ CUBE”) Cube Psytech, a biopharmaceutical and biotechnology company focused on sustainable, natural medicine that is developing a proprietary line of psilocybin microdosing health products with functional and psychedelic mushrooms is announcing a new supply agreement with Havn Life, a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products.

Based in Vancouver, Cube Psytech is currently raising funds for the construction and development of a Health Canada approved CGMP facility, as well as a research and development lab for product development. This agreement with HAVN Life will help CUBE with both the scientific research and the clinical trials in the future.

“We’re excited to build this relationship with HAVN Life,” says Cube Psytech CEO and Co-Founder Erick Factor. “We have been looking to secure a safe and standardized supply of natural psilocybin for the development of our products. We feel that HAVN Life is the ideal partner to fulfill this requirement,” he adds.

“We are very happy to add Cube Psytech to our list of supply partners,” says HAVN Life CEO, Tim Moore. “We’ve been working tirelessly to build out a full-fledged supply chain out of our facility in Jamaica as we continue to see demand for naturally derived psilocybin products. We are ready and willing to meet this demand,” he adds.

The agreement and supply of psilocybin to Cube Psytech will be in compliance with Health Canada guidelines.

On Behalf of The Board of Directors
Erick Factor
Chief Executive Officer

Contact: Erick Factor

Investor Relations: investors@cubepsytech.com

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.